All News

    Camrelizumab Combo Extends Survival in Metastatic Cervical Cancer

    October 20th 2025, 8:41pm

    Article

    Camrelizumab plus famitinib extended progression-free survival to 11.1 months versus 7.5 months with chemotherapy in recurrent or metastatic cervical cancer.

    Alecensa Improves 4-Year Survival in Early ALK-Positive Lung Cancer

    October 20th 2025, 8:15pm

    Article

    Alecensa achieved a 98.4% 4-year overall survival rate versus 92.4% with chemotherapy in resected ALK-positive early-stage lung cancer.

    Trodelvy Plus Keytruda Upholds Quality of Life in TNBC

    October 20th 2025, 7:29pm

    Article

    Trodelvy plus Keytruda may maintain quality of life and slow physical decline in metastatic triple-negative breast cancer.

    ADC Use Rapidly Growing in Metastatic Breast Cancer Treatment

    October 20th 2025, 5:38pm

    Article

    Antibody-drug conjugate treatment rates increased 3.7-fold from 2021 to 2023 for patients with metastatic breast cancer.

    Cancer Vaccine Plus Keytruda Slow Advanced Melanoma Progression

    October 20th 2025, 5:37pm

    Article

    The cancer vaccine IO102-IO103 plus Keytruda was associated with a clinically relevant improvement in median progression-free survival.

    Enhertu Plus Perjeta Boosts Survival in HER2-Positive Breast Cancer

    October 20th 2025, 3:14pm

    Article

    Enhertu plus Perjeta improved progression-free survival versus THP in patients with HER2-positive advanced or metastatic breast cancer across subgroups.

    Facing Mortality After Cancer, and Choosing to Live Fully

    October 20th 2025, 1:00pm

    Article

    After her follicular lymphoma diagnosis, Karen Cohn reflects on how cancer reshaped her view of mortality and her choice to keep living fully.

    Ivonescimab Combo Improves Progression-Free Survival in Advanced NSCLC

    October 19th 2025, 9:15pm

    Article

    Ivonescimab plus chemotherapy significantly improved progression-free survival versus Tevimbra advanced squamous non–small cell lung cancer.

    Sacituzumab Tirumotecan Improves Survival in EGFR-Mutated Non-Small Cell Lung Cancer

    October 19th 2025, 8:44pm

    Article

    Sacituzumab tirumotecan cut risk of progression or death by 51% versus chemotherapy in EGFR-mutated NSCLC after tyrosine kinase inhibitor resistance.

    Tiragolumab Treatment Combo Misses Mark in Advanced Liver Cancer

    October 19th 2025, 8:13pm

    Article

    Tiragolumab added to Tecentriq plus Avastin did not improve progression-free survival in untreated advanced hepatocellular carcinoma, phase 3 data show.